Tick-borne allergy drives Alpha-Gal market towards 8.5% expansion by 2034

Asia-Pacific outpaces regions as allergy awareness and healthcare systems scale up.

The Alpha-Gal Syndrome allergy market is projected to reach $163.16m by 2034, with a compound annual growth rate of 8.5%, driven by rising tick exposure and increasing diagnosed cases, according to Polaris Market Research.

The Asia-Pacific region is forecast to record the fastest growth throughout the period as healthcare systems expand, public awareness of rare allergic conditions rises, and diagnostic and research capacity grows across China, India, and Southeast Asia.

North America holds the largest market share in 2025 and maintains a leading position through 2034, supported by high exposure to tick-borne disease, established diagnostic infrastructure, and high healthcare expenditure in the United States and Canada.

The report attributes this to expanding tick habitats, including lone star tick activity, driven in part by climate change and land-use shifts, which increases case incidence and demand for diagnostic testing.

Diagnostic testing holds the largest share by offering, driven by blood-based immunoassays used to detect alpha-gal antibodies.

Antihistamines remain a primary drug class for symptom control, whilst epinephrine records growth potential due to its role in severe anaphylactic reactions.

Hospital pharmacies account for the largest distribution channel share, whilst online pharmacy channels expand access for ongoing care and telemedicine support.

Healthcare institutions, government agencies, and private investors are directing funding to allergy and immunology research.

Development activity focuses on diagnostic methods, clinical protocols, and early detection tools.